Abstract
A brief burst-suppressing isoflurane anesthesia has been shown to rapidly alleviate symptoms of depression in a subset of patients, but the neurobiological basis of these observations remains obscure. We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3β (GSK3β). Moreover, isoflurane affected neuronal plasticity by facilitating long-term potentiation in the hippocampus. We also found that isoflurane increased activity of the parvalbumin interneurons, and facilitated GABAergic transmission in wild type mice but not in transgenic mice with reduced TrkB expression in parvalbumin interneurons. Our findings strengthen the role of TrkB signaling in the antidepressant responses and encourage further evaluation of isoflurane as a rapid-acting antidepressant devoid of the psychotomimetic effects and abuse potential of ketamine.
Introduction
Major depression is a highly disabling psychiatric disorder, the most significant risk factor for suicide and one of the biggest contributors to the disease burden worldwide1, 2. Clinical effects of the classical antidepressants appear slowly and many patients respond to them poorly if at all3. Electroconvulsive therapy (ECT) remains the treatment of choice for treatment-resistant depression but repeated ECT produces cognitive side effects. Thus, there is a huge unmet medical need for more efficacious and rapid-acting treatments for major depression.
Discovery of the remarkable rapid antidepressant effect of the N-methyl-D-aspartate receptor (NMDA) blocker ketamine in treatment-resistant patients has inspired renewed enthusiasm towards antidepressant drug development4. However, the psychotomimetic properties and abuse potential limit the clinical use of ketamine5. Emerging evidence suggests that the rapid antidepressant effects of ketamine are mediated by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor dependent fast synaptic transmission and the release of brain-derived neurotrophic factor (BDNF) that further leads to increased signaling of the TrkB-mTOR (mammalian target of rapamycin) pathway, alterations in dendritic spine dynamics, synaptic plasticity and animal behaviour6–8. Inhibition of glycogen synthase kinase 3β (GSK3β) is another molecular signaling event recently implicated in the antidepressant mechanisms of ketamine9. These effects set forth by ketamine co-associate with altered GABAergic interneuron function10.
Brief deep isoflurane anesthesia has been shown to produce rapid antidepressant effects in both double-blind and open-label clinical studies11–14. The clinical observations have been, however, partially inconsistent (see refs 15, 16), which has reduced the interest to thoroughly evaluate isoflurane as an alternative for ECT and ketamine. To this end, we have translated the treatment concept into preclinical settings and evaluated its antidepressant-like and neurobiological effects in rodents. We show that a single isoflurane anesthesia rapidly transactivates TrkB, regulates the mTOR and GSK3β signaling pathways as well as activity and function of GABAergic interneurons, facilitates hippocampal long-term potentiation and produces antidepressant-like behavioural responses in rodents. These findings shed light on the neurobiological basis of clinically observed rapid-acting antidepressant effects of isoflurane and may become instrumental in dissecting shared mechanisms underlying rapid antidepressant responses.
Results
Antidepressant-like behavioural effects of isoflurane in rodents
The rat learned helplessness model (LH) has good face, construct and predictive validity regarding depression17, 18. Whereas long-term treatment with classical antidepressants is required to ameliorate the learned helplessness phenotype18, ketamine produces essentially similar antidepressant-like behavioural effect in the model already after a single treatment19. Consequently, we employed this model to investigate the potential antidepressant-like effects of isoflurane. Indeed, as shown in Fig. 1A, already a single exposure to isoflurane anesthesia produced an antidepressant-like effect (reduced failure to escape from the compartment where the animal receives footshocks) in the LH when the phenotype was assessed at 6 days post-treatment.
Chronic pain is strongly associated with depression20, 21 and previous studies show that persistent neuropathic pain induces behavioural abnormalities typical for depression and anxiety in mice22. Thus, we evaluated the antidepressant-like effects of a single isoflurane anesthesia treatment also in this model. As expected, mice subjected to the sciatic nerve cuffing showed depression-like phenotype (delayed latency to eat food pellet) in the novelty-suppressed feeding (NSF) test at 8-weeks post-surgery (Fig. 1B). Importantly, the phenotype was reversed in the nerve-cuffed animals exposed to isoflurane at 12 hours before the testing (Fig. 1B). The antidepressant-like effects of isoflurane appeared very rapidly in this test compared to classical antidepressants, which require weeks of repeated administration to show similar actions23. Of note, isoflurane did not have antinociceptive effects against the mechanical allodynia produced by the model (Fig. 1C).
Isoflurane anesthesia rapidly activates TrkB receptors
Essentially all antidepressants, including ketamine, have been shown to rapidly, within an hour, activate BDNF receptor TrkB and this effect is proposed to be critically involved in the mechanism of action of antidepressants7, 24–26. To test the intriguing possibility that isoflurane might bring about similar responses on TrkB, we subjected adult mice to a brief isoflurane treatment and collected brain samples and assayed the TrkB phosphorylation status. Deep burst-suppressing isoflurane anesthesia (induction 4%, maintenance ~2% ad 30 min; see ref. 27), which is shown to elicit rapid antidepressant effects in patients11, 13, robustly increased the phosphorylation of TrkB (pTrkB) in the medial prefrontal cortex (mPFC) (Fig. 2A), hippocampus (HC) (Fig. 2B) and the somatosensory cortex (Supplementary Figure 1) of adult naïve mice while subanesthetic isoflurane (0.3%) produced no such effects (Fig. 2C). The ability of isoflurane anesthesia to induce pTrkB is extremely fast and transient; a significant increase in pTrkB levels was observed within two minutes from the treatment onset and the TrkB phosphorylation returned close to baseline already at 15 min after the termination of anesthesia (Fig. 2D).
When transgenic mice over-expressing flag-tagged TrkB in neurons28 were treated with isoflurane, an increase in pTrkB was seen in the flag-antibody precipitated samples (Fig. 2E), demonstrating the specificity of the effect on TrkB. Since the transgene expression in this mouse line is directed to postnatal neurons28, this result also confirms that the pTrkB response takes place in neurons. Isoflurane treatment increased tyrosine phosphorylation of TrkB at the autocatalytic domain (Y706/7) and at the phospholipase-Cγ1 (PLCγ1) binding site (Y816) but not at the Shc binding site (Y515) (Fig. 2E), which is consistent with our previous findings with the classical monoamine-based antidepressants24, 26. Notably, similar changes in pTrkB were also observed after anesthesia with halothane or sevoflurane (Supplementary Figure 2).
TrkB activation is necessary for the antidepressant-like responses to isoflurane in the forced swim test
The forced swim test (FST) is an acute behavioural test used for screening of compounds with antidepressant potential in naïve animals29. Indeed, mice tested 15 minutes after the termination of isoflurane anesthesia showed significantly reduced immobility in the FST compared to sham-treated animals (Fig. 2F). The acute behavioural change produced by isoflurane anesthesia was likely not due to an overall increase in locomotor activity, since isoflurane-treated mice showed reduced rather than enhanced activity in the open field test (Supplementary Figure 3). Importantly, the effects of isoflurane in the FST were absent in mice over-expressing the dominant-negative truncated TrkB.T1 isoform (Fig. 2F). This finding is consistent with the loss of behavioural effects of classical antidepressants in these mice24 and suggests that TrkB is required also for the antidepressant-like effects of isoflurane in the FST.
Isoflurane regulates intracellular signaling implicated in antidepressant responses
Classical antidepressant drugs have been shown to activate the transcription factor cAMP response element binding protein (CREB) downstream of TrkB24, 26. Along with this change, ketamine has been shown to activate protein kinase B (Akt) and mTOR signaling pathways and phosphorylate GSK3β to the inhibitory Ser9 residue6, 7, 9. Ketamine-induced activation of mTOR further leads to phosphorylation and activation of p70S6k and eukaryotic initiation factor 4E binding protein 1 (4E-BP1). Isoflurane anesthesia produced remarkably similar phosphorylation changes on all these intracellular signaling molecules: the phosphorylation levels of CREBSer133, AktT308, mTORS2481, p70S6KT421/S424, 4EBP1T37/46 and GSK3βS9 were significantly increased at 30 minutes after the onset of isoflurane anesthesia in the mouse mPFC (Fig. 3A). Significant phosphorylations of CREBSer133, p70S6KT421/S424, 4EBP1T37/46 and GSK3βS9 were also observed in the HC after 30 min isoflurane treatment, whereas phosphorylation levels of AktT308 and mTORS2481 were not regulated (Fig. 3B). Similarly to the pTrkB response (Fig. 2D), these isoflurane-induced molecular changes were observed within minutes from the treatment onset (Fig. 3C). Collectively these data demonstrate that isoflurane anesthesia very rapidly regulates molecular events intimately associated with rapid antidepressant responses in brain areas implicated in the pathophysiology of major depression.
Isoflurane transactivates TrkB independently of BDNF and AMPA receptor signaling
Facilitation of AMPA receptor signaling and translation (and release) of BDNF through inhibition of eukaryotic elongation factor 2 (eEF2) are suggested to govern the effects of ketamine on TrkB6, 7, 19, 30, yet we found no clear evidence supporting these mechanisms for isoflurane. First, pretreatment with the AMPA receptor blocker NBQX (10 mg/kg, i.p.) for 10 minutes prior to isoflurane had no effect on the isoflurane-induced TrkB phosphorylation and downstream signaling (Fig. 4A). Moreover, phosphorylation of eEF2 and levels of BDNF (both mRNA and protein) remained unaltered by isoflurane at the time of TrkB phosphorylation (Fig. 4B–D). To investigate the role of BDNF more directly, we performed isoflurane-induced TrkB phosphorylation analyses in mice homozygous for a conditional deletion of BDNF specifically in CaMKII-positive neurons. Importantly, isoflurane readily activates TrkB in the hippocampus of these mice (Fig. 4E) even though the BDNF protein levels are undetectable (Fig. 4D). Notably, essentially similar BDNF-independent acute TrkB (trans)activation has been observed with classical antidepressant imipramine31.
Isoflurane does not regulate dendritic spine formation and turnover in the adult mouse cortex
Ketamine has been shown to rapidly – within 24-hours – promote spine recovery in the PFC of stressed rats by enhancing the mTOR-p70S6K signaling pathway6. The ability of isoflurane to readily activate this very same molecular pathway prompted us investigating its effects on dendritic spines 24 hours post-anesthesia. However, the spine densities were not significantly different from that found in the control mice in fixed sections of the PFC, HC or the somatosensory cortex (Fig. 5). Since fixed tissue preparation could undermine changes in spine dynamics, we used in vivo 2-photon time-lapse microscopy to image individual dendritic spines in the same (head-fixed but otherwise freely moving in the Mobile HomeCage32) mouse at 24 hours before (control condition), immediately before and at 24 hours after a brief isoflurane anesthesia. Because the PFC is not easily accessible to in vivo 2-photon imaging, we focused on the somatosensory cortex, where isoflurane also activates the TrkB-p70S6k signaling pathway (Supplementary Figure 1). Spine formation and elimination rates remained unchanged within 24 hours before and 24 hours after isoflurane, indicating that neither spine density nor spine dynamics were significantly affected by isoflurane anesthesia in this region (Fig. 6).
A brief isoflurane treatment leads to the facilitation of hippocampal synaptic strength
TrkB signaling importantly regulates neuronal plasticity such as long-term potentiation (LTP)33. Notably, facilitation of LTP has been implicated in the antidepressant response5, 34. We therefore used electrophysiology in acute brain slices from mice treated with isoflurane 24 hours earlier to study field excitatory postsynaptic potentials (fEPSP) recorded in the stratum radiatum of the CA1 region of the HC and evoked by electrical stimulation of the Schaffer collateral pathway. Recordings of input–output relationship showed that isoflurane exposure 24 hours before accentuated basal synaptic transmission in the HC (Fig. 7A). Paired pulse facilitation was not affected by isoflurane implying unaltered release probability and presynaptic function (Fig. 7B). In slices prepared from mice treated with isoflurane 24 hours before, tetanic stimulation (100 Hz/1 s) produced a significantly higher long-term potentiation (LTP) of the fEPSPs than what was seen in the control slices (Fig. 7C) (see ref. 35). These effects of isoflurane on synaptic strength are reminiscent of the previously reported changes seen after a long-term treatment with the classical antidepressant fluoxetine, but they appear much faster36.
Isoflurane regulates the excitability of parvalbumin-containing interneurons through TrkB
To investigate cellular and network level correlates underlying isoflurane-induced facilitation of synaptic plasticity we performed FosB immunostainings on brain sections with the aim to identify neuronal populations showing sustained activity following isoflurane administration. Interestingly, parvalbumin interneurons within the HC (and cortex; Supplementary Figure 4) showed the most prominent FosB immunoreactivity 24 hours after a brief exposure to isoflurane (Fig. 8A,B). This observation prompted us to test the role of inhibitory interneurons further using pharmacological and genetic tools. Indeed, bath application of picrotoxin essentially abolished the accentuated LTP after isoflurane anesthesia, supporting a GABAA dependent mechanism (Fig. 8C). Moreover, spontaneous inhibitory postsynaptic currents (IPSCs) were significantly increased in CA1 pyramidal neurons in slices obtained from animals treated with isoflurane 24 hours before (Fig. 8D). This effect was due to altered excitability of GABAergic interneurons rather than changes in GABA release, since no difference in miniature IPSCs were detected between control and isoflurane treated mice (Fig. 8E,F). To investigate the potential involvement of TrkB in these effects produced by isoflurane we performed electrophysiological studies in mice with reduced TrkB expression specifically in the parvalbumin interneurons (PV-TrkB+/− heterozygous cKO mice). Importantly, whereas the effect of isoflurane on spontaneous IPSCs was readily recapitulated in hippocampal slices obtained from control animals, such effect was blunted in slices obtained from PV-TrkB+/− mice (Fig. 8G). Altogether these studies suggest that a brief isoflurane anesthesia brings about sustained TrkB dependent changes on the excitability of parvalbumin containing GABAergic interneurons.
Discussion
Our study shows that isoflurane, at dosing regimen shown to bring about antidepressant effects in clinical studies11, 13, 14, induces TrkB phosphorylation and downstream signaling in the brain regions implicated in antidepressant responses, and that this signaling is accompanied by long-lasting, TrkB dependent plasticity-related physiological and behavioural responses. Previous observations have suggested that the activation of TrkB and subsequent intracellular signaling are required for the behavioural effects of clinically used antidepressants, including the rapid-acting antidepressant ketamine7, 24. The observation that TrkB is also activated by and required for the behavioural effects of isoflurane in the FST strengthens the role for TrkB signaling as the common pathway for antidepressant actions.
While many molecular and cellular mechanisms activated by isoflurane resemble those induced by ketamine, there seem to be important differences in the action of these two drugs. It has been proposed that ketamine facilitates AMPA receptor activation, which subsequently leads to BDNF release and TrkB activation. Our data suggest that isoflurane (and classical antidepressants31) induces TrkB activation without the involvement of BDNF and AMPA receptor activation7. Notably, several neurotransmitters and modulators have been shown to transactivate receptor tyrosine kinases, such as TrkB, through the regulation of Src family kinases37–39. Whether such mechanism underlies the isoflurane-induced TrkB activation remains to be investigated. Moreover, isoflurane significantly potentiated glutamatergic synaptic transmission but did not seem to affect synaptic structure (i.e. the morphology and turnover of dendritic spines), while ketamine has been shown to affect both the structure and function of the excitatory synapses6, 30. The lack of effects of isoflurane on dendritic spine dynamics is consistent with previous observations showing that anesthetics, such as isoflurane, significantly regulate dendritic spine number and morphology during brain growth spurt, but not in the adult brain40, 41. Unlike ketamine, however, the effects of isoflurane on dendritic spines have been investigated in animals not subjected to chronic stress. Therefore, the effects of isoflurane and ketamine on molecular signaling events, dendritic spines and neuronal plasticity should be investigated and directly compared in naïve animals and in various animal models of depression (e.g. social defeat stress, chronic unpredictable mild stress). The potential differences in the mechanisms of action between ketamine and isoflurane may become instrumental in the attempts to focus drug discovery efforts towards the pathways activated by both compounds.
Reduced concentration of GABA is implicated in pathophysiology of depression and it has been proposed that many of the currently used antidepressants ultimately act through modulation of GABAergic transmission42, 43. The observation that isoflurane treatment led to changes in the activity of parvalbumin (PV) positive interneurons is consistent with the idea that the primary effect of isoflurane resides in the GABAergic PV interneurons, which regulate the activity of glutamatergic principal neurons via perisomatic inhibition10. Importantly, tetanic stimulation can result in interneuron-driven GABAergic excitation, leading to synchronous spiking in hippocampal pyramidal neurons and thereby promoting LTP induction44, 45.
Remarkably, clinical studies conducted decades ago have shown that isoflurane therapy that induces burst suppressing pattern in the EEG (electroencephalogram) produces a robust and rapid antidepressant response in a subset of treatment-resistant depressed patients11, 13. Although some subsequent trials were unable to replicate these findings15, 16, a recent positive replication by Weeks et al. has renewed the interest towards isoflurane as an antidepressant therapy14. The antidepressant response of isoflurane appears comparable in magnitude to that produced by the ECT, but faster in onset; a significant antidepressant effect was observed after a single isoflurane treatment13. Our current results provide plausible neurobiological basis for the rapid-acting antidepressant efficacy of isoflurane and encourage its further clinical evaluation in depressed patients.
This report has significant implications also outside antidepressant field. Isoflurane is a commonly used anesthetic agent in experimental research. With increased use of electrophysiological, imaging and optogenetic methods requiring surgical operations, mice are often exposed to isoflurane anesthesia prior to behavioural testing. Therefore, the long-lasting physiological and behavioural responses to isoflurane treatment uncovered here should be taken into account when designing and interpreting behavioural assessments in animals previously anesthetized with isoflurane. Given the pronounced effects of anesthetics on several molecular pathways in naïve animals27, the use of anesthesia should be taken into account in experimental research when interpreting the data.
Materials and Methods
Detailed description of Materials and Methods are provided in the Supplementary Information file.
Animals
Adult C57BL/6J, BDNF2L/2LCk-Cre (ref. 46), B6.Cg-Tg(Thy1- YFPH)2Jrs/J, TrkBfl°x/−:PV-Cre+/− (refs 47, 48) heterozygous conditional knockout mice and transgenic mice over-expressing flag-tagged TrkB or truncated TrkB.T128, 49, 50 and their wild-type littermates were used. Adult male Wistar rats were used for learned helplessness test. The learned helplessness studies were conducted in conformity with the Brazilian Council for the Control of Animals under Experiment (CONCEA) and were approved by the local ethical committee of University of São Paulo at Ribeirão Preto campus. The experiments involving neuropathic pain model were performed in accordance with guidelines for animal experimentation of the International Association for the Study of Pain (IASP) and European Communities Council Directive 86/6609/EEC and were approved by the local ethical committee of the University of Strasbourg (CREMEAS, n°AL-04). The experiments involving conditional BDNF mutant mice were performed in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals guidelines and were approved by the Institutional Animal Care and Use Committee at Tufts University. Rest of the experiments were carried out according to the guidelines of the Society for Neuroscience and were approved by the County Administrative Board of Southern Finland (License numbers: ESLH-2007-09085/Ym-23, ESAVI/7551/04.10.07/2013).
In vivo pharmacological treatments
The following drugs were used: isoflurane (inhalation; anesthesia: induction ~4%, maintenance ~1–2%; see ref. 27), sevoflurane (inhalation; anesthesia: induction ~8%, maintenance ~4%), halothane (as for isoflurane) and NBQX (i.p., 10 mg/kg; in saline).
Immunoprecipitation and western blot
The brain samples were homogenized in NP lysis buffer26, centrifuged (16000 g, 15 min, +4 °C) and the resulting supernatant used for analyses. Samples were separated with SDS-PAGE and blotted to PVDF membrane. Membranes were incubated with antibodies directed against phosphorylated or non-phosphorylated forms of Trk/TrkB, CREB, Akt, mTOR, p70S6K, 4E-BP1, GSK3β, eEF2, BDNF and GAPDH. Following consecutive washes and horseradish peroxidase conjugated secondary antibody incubations immunoreactive bands were visualized using enhanced chemiluminescence using a standard camera.
qRT-PCR and ELISA
Total Bdnf mRNA levels were measured using quantitative RT-PCR as described51. BDNF protein levels were analyzed using a commercial ELISA kit.
Spine analysis from fixed tissue
B6.Cg-Tg(Thy1- YFPH)2Jrs/J mice were transcardially perfused with 4% PFA at 24 h after isoflurane/sham treatment under pentobarbital anesthesia. Floating sections (50 μm) were cut using a vibratome and processed for YFP immunofluorescence histochemistry using standard techniques. Images were obtained using confocal microscope and pyramidal neurons from the mPFC and SSCx were selected with the following criteria: intense fluorescence, soma located in layer V, and primary apical dendrite >200 μm long. We imaged the dendrites in three ~65 μm long segments (proximal/medial/distal). We distinguished three types of dendritic spines: (i) stubby; (ii) mushroom and; (iii) filopodia/thin.
In vivo two-photon microscopic imaging in awake mice
B6.Cg-Tg(Thy1- YFPH)2Jrs/J mice and Mobile HomeCage system (Neurotar Ltd., Finland) were used for the analysis of dendritic spine turnover in SSCx (layer 1) in an awake in vivo imaging through cranial window implanted onto the skull above the somatosensory cortex. Five different dendritic segments from 4 different areas were analyzed per animal to study the time-lapse spine turnover52. The spine formation and elimination rates were calculated as the number of spines that have appeared or disappeared, respectively at a given time point compared to the previous time point relative to the total number of spines present at that or the previous time, respectively.
Immunohistochemistry
The tissue was processed as free-floating sections. After blocking and permeabilization the sections were incubated for 48 h at 4 °C with a cocktail containing IgG mouse anti-Somatostatin, IgG guinea pig anti-Parvalbumin and IgG rabbit anti-FosB. After washing the sections were incubated with a cocktail containing the fluorescence conjugated secondary antibodies. Washed sections were mounted on slides and coverslipped using fluorescence mounting medium (Dako).
Electrophysiological recordings
Hippocampal slices (400 μm) were cut with a vibratome as described53. Extracellular recordings from CA1 stratum radiatum were obtained with aCSF (artificial cerebrospinal fluid) filled glass microelectrodes (2–5 MΩ) using an Axopatch 200B amplifier. Field excitatory potentials (fEPSP) were evoked with a bipolar stimulating electrode placed in the Schaffer collateral pathway. LTP was induced by 100-Hz tetanic stimulation for 1 s. The level of LTP was measured as a percentage increase of the fEPSP slope, averaged at a 1-min interval 30 min after the tetanus, and compared to the averaged baseline fEPSP slope. For paired-pulse stimulation, interpulse intervals from 10 to 200 ms were tested. To antagonize fast GABAA synaptic transmission picrotoxin (PiX; 100 µM) was used. WinLTP (0.95b or 0.96, www.winltp.com) was used for data acquisition54. To investigate inhibitory postsynaptic currents, 25 µM MK-801, 5 µM L-689-560 and 20 µM NBQX were included in the aCSF to antagonize NMDA and AMPA receptors. Whole cell voltage clamp recordings (−70 mV) from CA1 neurons were obtained with glass microelectrodes (4.5–6 MOhm) using a Multiclamp 700A amplifier (Axon Instruments, USA). To record miniature IPSCs, 1 µM TTX was added to aCSF. The data analysis was made with Mini Analysis Program, version 5.6.6 (Synaptosoft, USA).
Behavioural tests
Learned Helplessness test
The test was performed as described55. The protocol includes a pre-test session (PT) with 40 unescapable footshocks (0.4 mA, per 10 s) and on the 7th day a test session (T) in which 30 escapable footshocks (0.4 mA, per 10 s) are preceded (5 s) by an alarm tone (60 dB, 670 Hz). In the test session the shock could be interrupted or avoided by the animal if it crosses to the other compartment of the chamber during the tone presentation or during the footshock application. Twenty-four hours after the PT the animals were anesthetized with isoflurane.
Neuropathic pain model of depression
Neuropathic pain was induced by placing a cuff around the main branch of the right sciatic nerve under anesthesia22, 56. Sham-operated mice underwent the same procedure without cuff. The mechanical threshold of hindpaw withdrawal was evaluated using von Frey filaments56, 57. To assess anxiodepressive phenotype the novelty suppressed feeding (NSF) test was done at 12th hour after the isoflurane/sham treatment22, 23.
Forced swim test
A mouse was placed into a glass cylinder (diameter 19 cm, height 24 cm) filled with water (21 ± 1 °C) to the height of 14 cm. Overall immobility was measured during the 6-minute testing period.
Open field test
General locomotor activity was investigated for 30 min in an illuminated (300 lux) transparent cage (length 28.5 × height 8.5 × width 20 cm). Interruptions of infrared photo beams were used to calculate the overall distance traveled (cm).
Statistical analysis
Results are represented as mean ± SEM (standard error of mean) unless otherwise stated. For statistical analysis two-sided tests including unpaired two-tailed Student’s t-test, Mann Whitney U test (non-normally distributed data), one-way analysis of variance (ANOVA), mixed model ANOVA, two-way ANOVA, Pearson’s χ2 test and Spearman’s correlation test were used. Levene’s test was used to define the equality of variances. If the variances differed significantly non-parametric test was used. Post hoc analysis was conducted with Tukey HSD or Dunnett’s test. Statistically significant p value was set to ≤ 0.05. Outliers were considered as values differing more than 2x standard deviation from the mean of the group. To calculate the proper sample sizes we used power calculations (α = 0.05 and power 0.80) and estimated the standard deviations and effect sizes based on our previous experience and literature.
Electronic supplementary material
Acknowledgements
The authors would like to thank Outi Nikkilä, Nina Karpova, Vootele Võikar, Mikko Airavaara, Jussi Kupari, Yasmin Hohn, Sissi Pastell, Maria Partanen and Virpi Perko for technical assistance. This study has been supported by grants from the European Research Council (iPlasticity, #322742) (E.C.), Sigrid Jusélius Foundation (E.C., T.T.), Academy of Finland (E.C., T.R., T.T.), Orion-Farmos Research Foundation (H.An., S.K.) and Doctoral Program Brain & Mind (H.An.).
Author Contributions
H.An., I.Y., E.C. and T.R. designed the experiments, H.An., P.S., M.R., D.P., I.Y., P.C., S.K., R.G., J.L., H.Au., L.V., M.K., V.S., S.J., L.K., T.T., T.R., J.C., S.L., performed the experiments, H.An., D.P., R.G., T.T. performed statistical analyses, H.An., E.C. and T.R. wrote the paper.
Competing Interests
L.K. is a paid employee in Neurotar Ltd.
Footnotes
Electronic supplementary material
Supplementary information accompanies this paper at doi:10.1038/s41598-017-08166-9
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Eero Castrén, Email: eero.castren@helsinki.fi.
Tomi Rantamäki, Email: tomi.rantamaki@helsinki.fi.
References
- 1.Kessler RC, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA J. Am. Med. Assoc. 2003;289:3095–3105. doi: 10.1001/jama.289.23.3095. [DOI] [PubMed] [Google Scholar]
- 2.Olesen J, et al. The economic cost of brain disorders in Europe. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 2012;19:155–162. doi: 10.1111/j.1468-1331.2011.03590.x. [DOI] [PubMed] [Google Scholar]
- 3.Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry. 2003;53:649–659. doi: 10.1016/S0006-3223(03)00231-2. [DOI] [PubMed] [Google Scholar]
- 4.Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry. 2000;47:351–354. doi: 10.1016/S0006-3223(99)00230-9. [DOI] [PubMed] [Google Scholar]
- 5.Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68–72. doi: 10.1126/science.1222939. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Li N, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964. doi: 10.1126/science.1190287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Autry AE, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–95. doi: 10.1038/nature10130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zanos P, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486. doi: 10.1038/nature17998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Beurel E, Song L, Jope R. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol. Psychiatry. 2011;16:1068–1070. doi: 10.1038/mp.2011.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Miller OH, Moran JT, Hall BJ. Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology. 2016;100:17–26. doi: 10.1016/j.neuropharm.2015.07.028. [DOI] [PubMed] [Google Scholar]
- 11.Langer G, Neumark J, Koinig G, Graf M, Schönbeck G. Rapid psychotherapeutic effects of anesthesia with isoflurane (ES narcotherapy) in treatment-refractory depressed patients. Neuropsychobiology. 1985;14:118–120. doi: 10.1159/000118216. [DOI] [PubMed] [Google Scholar]
- 12.Engelhardt W, Carl G, Hartung E. Intra-individual open comparison of burst-suppression-isoflurane-anaesthesia versus electroconvulsive therapy in the treatment of severe depression. Eur. J. Anaesthesiol. 1993;10:113–118. [PubMed] [Google Scholar]
- 13.Langer G, et al. Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. A double-blind comparison with electroconvulsive treatment. Neuropsychobiology. 1995;31:182–194. doi: 10.1159/000119190. [DOI] [PubMed] [Google Scholar]
- 14.Weeks HR, III, et al. Antidepressant and Neurocognitive Effects of Isoflurane Anesthesia versus Electroconvulsive Therapy in Refractory Depression. PLoS ONE. 2013;8:e69809. doi: 10.1371/journal.pone.0069809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Greenberg LB, Gage J, Vitkun S, Fink M. Isoflurane Anesthesia Therapy: A Replacement for ECT in Depressive Disorders? Convuls. Ther. 1987;3:269–277. [PubMed] [Google Scholar]
- 16.García-Toro M, et al. Inefficacy of burst-suppression anesthesia in medication-resistant major depression: a controlled trial. J. ECT. 2001;17:284–288. doi: 10.1097/00124509-200112000-00009. [DOI] [PubMed] [Google Scholar]
- 17.Czéh, B., Fuchs, E., Wiborg, O. & Simon, M. Animal models of major depression and their clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, doi:10.1016/j.pnpbp.2015.04.004 (2015). [DOI] [PubMed]
- 18.Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002;23:238–245. doi: 10.1016/S0165-6147(02)02017-5. [DOI] [PubMed] [Google Scholar]
- 19.Maeng S, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry. 2008;63:349–352. doi: 10.1016/j.biopsych.2007.05.028. [DOI] [PubMed] [Google Scholar]
- 20.Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 2003;163:2433–2445. doi: 10.1001/archinte.163.20.2433. [DOI] [PubMed] [Google Scholar]
- 21.Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152:2836–2843. doi: 10.1016/j.pain.2011.09.014. [DOI] [PubMed] [Google Scholar]
- 22.Yalcin I, et al. A time-dependent history of mood disorders in a murine model of neuropathic pain. Biol. Psychiatry. 2011;70:946–953. doi: 10.1016/j.biopsych.2011.07.017. [DOI] [PubMed] [Google Scholar]
- 23.Santarelli L, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–809. doi: 10.1126/science.1083328. [DOI] [PubMed] [Google Scholar]
- 24.Saarelainen T, et al. Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects. J. Neurosci. 2003;23:349–357. doi: 10.1523/JNEUROSCI.23-01-00349.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Koponen E, et al. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell. Mol. Neurobiol. 2005;25:973–980. doi: 10.1007/s10571-005-8468-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Rantamäki T, et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2007;32:2152–2162. doi: 10.1038/sj.npp.1301345. [DOI] [PubMed] [Google Scholar]
- 27.Kohtala S, et al. Brief Isoflurane Anesthesia Produces Prominent Phosphoproteomic Changes in the Adult Mouse Hippocampus. ACS Chem. Neurosci. 2016;7:749–756. doi: 10.1021/acschemneuro.6b00002. [DOI] [PubMed] [Google Scholar]
- 28.Koponen E, et al. Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety, and facilitated learning. Mol. Cell. Neurosci. 2004;26:166–181. doi: 10.1016/j.mcn.2004.01.006. [DOI] [PubMed] [Google Scholar]
- 29.Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol. Psychiatry. 2004;9:326–357. doi: 10.1038/sj.mp.4001457. [DOI] [PubMed] [Google Scholar]
- 30.Li N, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry. 2011;69:754–761. doi: 10.1016/j.biopsych.2010.12.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Rantamäki T, et al. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PloS One. 2011;6:e20567. doi: 10.1371/journal.pone.0020567. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kislin, M. et al. Flat-floored air-lifted platform: a new method for combining behavior with microscopy or electrophysiology on awake freely moving rodents. J. Vis. Exp. JoVE e51869, doi:10.3791/51869 (2014). [DOI] [PMC free article] [PubMed]
- 33.Castrén, E., & Antila, H. Neuronal plasticity and neurotrophic factors in drug responses. Mol. Psychiatry, doi:10.1038/mp.2017.61 (2017). [DOI] [PMC free article] [PubMed]
- 34.Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 2010;70:289–297. doi: 10.1002/dneu.20758. [DOI] [PubMed] [Google Scholar]
- 35.Rammes G, et al. Isoflurane anaesthesia reversibly improves cognitive function and long-term potentiation (LTP) via an up-regulation in NMDA receptor 2B subunit expression. Neuropharmacology. 2009;56:626–636. doi: 10.1016/j.neuropharm.2008.11.002. [DOI] [PubMed] [Google Scholar]
- 36.Wang J-W, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. Off. J. Soc. Neurosci. 2008;28:1374–1384. doi: 10.1523/JNEUROSCI.3632-07.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Lee FS, Rajagopal R, Chao MV. Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors. Cytokine Growth Factor Rev. 2002;13:11–17. doi: 10.1016/S1359-6101(01)00024-7. [DOI] [PubMed] [Google Scholar]
- 38.Huang YZ, Pan E, Xiong Z-Q, McNamara JO. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron. 2008;57:546–558. doi: 10.1016/j.neuron.2007.11.026. [DOI] [PubMed] [Google Scholar]
- 39.Rajagopal R, Chao MV. A role for Fyn in Trk receptor transactivation by G-protein-coupled receptor signaling. Mol. Cell. Neurosci. 2006;33:36–46. doi: 10.1016/j.mcn.2006.06.002. [DOI] [PubMed] [Google Scholar]
- 40.Briner A, et al. Volatile anesthetics rapidly increase dendritic spine density in the rat medial prefrontal cortex during synaptogenesis. Anesthesiology. 2010;112:546–556. doi: 10.1097/ALN.0b013e3181cd7942. [DOI] [PubMed] [Google Scholar]
- 41.Briner A, et al. Developmental Stage-dependent persistent impact of propofol anesthesia on dendritic spines in the rat medial prefrontal cortex. Anesthesiology. 2011;115:282–293. doi: 10.1097/ALN.0b013e318221fbbd. [DOI] [PubMed] [Google Scholar]
- 42.Luscher B, Shen Q, Sahir N. The GABAergic Deficit Hypothesis of Major Depressive Disorder. Mol. Psychiatry. 2011;16:383–406. doi: 10.1038/mp.2010.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Méndez P, Pazienti A, Szabó G, Bacci A. Direct alteration of a specific inhibitory circuit of the hippocampus by antidepressants. J. Neurosci. Off. J. Soc. Neurosci. 2012;32:16616–16628. doi: 10.1523/JNEUROSCI.1720-12.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Ellender TJ, Raimondo JV, Irkle A, Lamsa KP, Akerman CJ. Excitatory effects of parvalbumin-expressing interneurons maintain hippocampal epileptiform activity via synchronous afterdischarges. J. Neurosci. Off. J. Soc. Neurosci. 2014;34:15208–15222. doi: 10.1523/JNEUROSCI.1747-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Taira T, Lamsa K, Kaila K. Posttetanic excitation mediated by GABA(A) receptors in rat CA1 pyramidal neurons. J. Neurophysiol. 1997;77:2213–2218. doi: 10.1152/jn.1997.77.4.2213. [DOI] [PubMed] [Google Scholar]
- 46.Rios M, et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol. Endocrinol. Baltim. Md. 2001;15:1748–1757. doi: 10.1210/mend.15.10.0706. [DOI] [PubMed] [Google Scholar]
- 47.Hippenmeyer S, et al. A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol. 2005;3:e159. doi: 10.1371/journal.pbio.0030159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Minichiello L, et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron. 1999;24:401–414. doi: 10.1016/S0896-6273(00)80853-3. [DOI] [PubMed] [Google Scholar]
- 49.Saarelainen T, et al. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons have impaired long-term spatial memory but normal hippocampal LTP. Synap. N. Y. N. 2000;38:102–104. doi: 10.1002/1098-2396(200010)38:1<102::AID-SYN11>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
- 50.Saarelainen T, et al. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons show increased susceptibility to cortical injury after focal cerebral ischemia. Mol. Cell. Neurosci. 2000;16:87–96. doi: 10.1006/mcne.2000.0863. [DOI] [PubMed] [Google Scholar]
- 51.Rantamäki T, et al. The Impact of Bdnf Gene Deficiency to the Memory Impairment and Brain Pathology of APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease. PLoS ONE. 2013;8:e68722. doi: 10.1371/journal.pone.0068722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Chen JL, et al. Clustered dynamics of inhibitory synapses and dendritic spines in the adult neocortex. Neuron. 2012;74:361–373. doi: 10.1016/j.neuron.2012.02.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Pavlov I, Rauvala H, Taira T. Enhanced hippocampal GABAergic inhibition in mice overexpressing heparin-binding growth-associated molecule. Neuroscience. 2006;139:505–511. doi: 10.1016/j.neuroscience.2005.11.070. [DOI] [PubMed] [Google Scholar]
- 54.Anderson WW, Collingridge GL. Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions. J. Neurosci. Methods. 2007;162:346–356. doi: 10.1016/j.jneumeth.2006.12.018. [DOI] [PubMed] [Google Scholar]
- 55.Joca SRL, Padovan CM, Guimarães FS. Activation of post-synaptic 5-HT(1A) receptors in the dorsal hippocampus prevents learned helplessness development. Brain Res. 2003;978:177–184. doi: 10.1016/S0006-8993(03)02943-3. [DOI] [PubMed] [Google Scholar]
- 56.Bohren Y, et al. Antidepressants suppress neuropathic pain by a peripheral β2-adrenoceptor mediated anti-TNFα mechanism. Neurobiol. Dis. 2013;60:39–50. doi: 10.1016/j.nbd.2013.08.012. [DOI] [PubMed] [Google Scholar]
- 57.Yalcin I, et al. beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann. Neurol. 2009;65:218–225. doi: 10.1002/ana.21542. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.